(NASDAQ: BMEA) Biomea Fusion's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Biomea Fusion's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BMEA's revenue for 2024 to be $358,893,600, with the lowest BMEA revenue forecast at $358,893,600, and the highest BMEA revenue forecast at $358,893,600. On average, 1 Wall Street analysts forecast BMEA's revenue for 2025 to be $538,340,400, with the lowest BMEA revenue forecast at $538,340,400, and the highest BMEA revenue forecast at $538,340,400.
In 2026, BMEA is forecast to generate $388,322,875 in revenue, with the lowest revenue forecast at $238,305,350 and the highest revenue forecast at $538,340,400.